Komori
Tsubota Laboratory (4890) · RiskRestated

Risk of a gap between R&D investment and results

First written in FY2022. 3 of 4 entries say "Restated". Latest entry: FY2026.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022 – FY20262022: 120222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Risk of R&D investments failing to deliver resultsA theme 116 companies write about · 116 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 14 of 29 companies on the "Worse" side.

74 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 116 companies compared. The sentences above are computed from all 116.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「The Company plans to continue investing in expenses for specified clinical research and clinical trials after 2026. However, if R&D results diverge significantly from targets, they may affect business performance and other matters.」

    Reconfirms the plan to invest in R&D funds after 2026 and the risk that results may diverge from targets.
  2. FY2024RestatedAnnual report

    「The Company plans to continue investing in expenses for specified clinical research and clinical trials after 2024. However, if R&D results diverge significantly from targets, they may affect business performance and other matters.」

    Reconfirms the plan to invest in R&D funds after 2024 and the risk that results may diverge from targets.
  3. FY2023RestatedAnnual report

    「The Company plans to continue investing in expenses for specified clinical research and clinical trials after 2023. However, if R&D results diverge significantly from targets, they may affect business performance and other matters.」

    Restates the risk that results may diverge from targets while continuing to invest in R&D resources.
  4. FY2022First statedAnnual report

    「The Company plans to continue investing in expenses for specified clinical research and clinical trials after 2022, following its listing. However, if R&D results diverge significantly from targets, they may affect business performance and other matters.」

    Discloses the failure to achieve expected results after investment in R&D and clinical trial expenses as a risk within 3 years.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Tsubota Laboratory yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of a gap between R&D investment and results | Tsubota Laboratory Incorporated (4890) | Komori